Artículos de revistas
Design, Synthesis And Biological Evaluation Of Hybrid Bioisoster Derivatives Of N-acylhydrazone And Furoxan Groups With Potential And Selective Anti-trypanosoma Cruzi Activity
Registro en:
European Journal Of Medicinal Chemistry. Elsevier Masson Sas, v. 82, n. , p. 418 - 425, 2014.
2235234
10.1016/j.ejmech.2014.05.077
2-s2.0-84902507567
Autor
Massarico Serafim R.A.
Goncalves J.E.
De Souza F.P.
De Melo Loureiro A.P.
Storpirtis S.
Krogh R.
Andricopulo A.D.
Dias L.C.
Ferreira E.I.
Institución
Resumen
Hybrid bioisoster derivatives from N-acylhydrazones and furoxan groups were designed with the objective of obtaining at least a dual mechanism of action: cruzain inhibition and nitric oxide (NO) releasing activity. Fifteen designed compounds were synthesized varying the substitution in N-acylhydrazone and in furoxan group as well. They had its anti-Trypanosoma cruzi activity in amastigotes forms, NO releasing potential and inhibitory cruzain activity evaluated. The two most active compounds (6, 14) both in the parasite amastigotes and in the enzyme contain the nitro group in para position of the aromatic ring. The permeability screening in Caco-2 cell and cytotoxicity assay in human cells were performed for those most active compounds and both showed to be less cytotoxic than the reference drug, benznidazole. Compound 6 was the most promising, since besides activity it showed good permeability and selectivity index, higher than the reference drug. Thereby the compound 6 was considered as a possible candidate for additional studies. © 2014 Elsevier Masson SAS. All rights reserved. 82
418 425 Coura, J.R., Dias, J.C.P., Epidemiology, control and surveillance of Chagas disease - 100 years after its discovery (2009) Mem. Inst. Oswaldo Cruz, 104, pp. 31-40 Anis, R.J., Anis, R., Marin-Neto, J.A., Chagas disease (2010) Lancet, 375, pp. 1388-1402 (2013), http://www.who.int/mediacentre/factsheets/fs340/en/index.html, World Health Organization, WHOGascon, J., Bern, C., Pinazo, M.J., Chagas disease in Spain, the United States and other non-endemic countries (2010) Acta Trop., 115, pp. 22-27 Nunes, M.C.P., Dones, W., Montillo, C.A., Encina, J.J., Ribeiro, A.L., Chagas disease: An overview of clinical and epidemiological aspects (2013) J. A. Coll. Cardiol., 62, pp. 767-776 Dias, L.C., Dessoy, M.A., Silva, J.N.S., Thiemann, O.H., Oliva, G., Andricopulo, A.D., Quimioterapia da doença de Chagas: Estado da arte e perspectivas no desenvolvimento de novos fármacos (2009) Quim. Nova, 32, pp. 2444-2457 Alves, R.M., Thomaz, R.P., Almeida, E.A., Wanderley, J.S., Guariento, M.E., Chagas disease and egeing: The coexistence of other chronic disease with Chagas disease in elderly patients (2009) Rev. Soc. Bras. Med. Trop., 42, pp. 622-628 Barreiro, E.J., Fraga, C.A.M., (2008) Química Medicinal: As Bases Moleculares da Ação Dos Fármacos, pp. 271-277. , second ed. Artmed Porto Alegre 343-345 Lima, L.M., Barreiro, E.J., Bioisosterism: A useful strategy for molecular modification and drug design (2005) Curr. Med. Chem., 12, pp. 23-49 Viegas-Junior, C., Danuello, A., Bolzani, V.S., Barreiro, E.J., Fraga, C.A.M., Molecular hybridization: A useful tool in the design of new drug prototypes (2007) Curr. Med. Chem., 14, pp. 1829-1852 Serafim, R.A.M., Primi, M.C., Trossini, G.H.G., Ferreira, E.I., Nitric oxide: State of the art in drug design (2012) Curr. Med. Chem., 19, pp. 385-405 Cerecetto, H., González, M., Anti-T. Cruzi agents: Our experience in the evaluation of more than five hundred compounds (2008) Mini-Rev. Med. Chem., 8, pp. 1355-1383 Silva, J.J.N., Guedes, P.M.M., Zottis, A., Balliano, T.L., Silva, F.O.N., Lopes, L.G.F., Ellena, J., Silva, J.S., Novel ruthenium complexesas potential drugs for Chagas's disease: Enzyme inhibition and in vitro/in vivo trypanocidal activity (2010) Br. J. Pharmacol., 160, pp. 260-269 Brunet, L.R., Nitric oxide in parasitic infections (2001) Int. Immunopharmacol., 1, pp. 1457-1467 Romeiro, N.C., Aguirre, G., Hernandez, P., Gomzalez, M., Cerecetto, H., Aldana, I., Perez-Silanes, S., Lima, L.M., Synthesis, trypanocidal activity and docking studies of novel quinaxoline-N-acylhydrazones, designed as cruzain inhibitors candidates (2009) Bioorg. Med. Chem., 17, pp. 641-652 Moreira, D.R.M., Leite, A.C.L., Santos, R.R., Soares, M.B.P., Approaches for the development of new anti-Trypanosoma cruzi agents (2009) Curr. Drugs Targets, 10, pp. 212-231 McGrath, M.E., Eakin, A.E., Engel, J.C., McKerrow, J.H., Craik, C.S., Fletterick, R.J., The crystal structure of cruzain: A therapeutic target for Chagas' disease (1995) J. Mol. Biol., 247, pp. 251-259 Judice, W.A.S., Cezari, M.H.S., Lima, A.P.C.A., Scharfstein, J., Chagas, J.R., Tersariol, I.L.S., Juliano, M.A., Juliano, L., Comparison of the specificity, stability and individual rate constants with respective activation parameters for the peptidase activity of cruzipain and its recombinant form, cruzain, from Trypanosoma cruzi (2001) Eur. J. Biochem., 268, pp. 6578-6586 Wilkinson, S.R., Bot, C., Kelly, J.M., Hall, B.S., Trypanocidal activity of nitroaromatic prodrugs: Current treatments and future perspectives (2011) Curr. Med. Chem., 11, pp. 2072-2084 (1998) MarvinView 5.4.0. - Free License, , ChemAxon Ltd Hernandez, P., Rojas, R., Gilman, R.H., Sauvain, M., Lima, L.M., Barreiro, E.J., Gonzalez, M., Cerecetto, H., Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates (2013) Eur. J. Med. Chem., 59, pp. 64-74 Storpirtis, S., Gonçalves, J.E., Chiann, C., Gai, M.N., Biofarmacotécnica-série ciências farmacêuticas (2009) Guanab. Koogan, pp. 204-211 Souza, J., Benet, L.Z., Huang, Y., Storpirtis, S., Comparison of bidirectional Lamavudine and Zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers (2009) J. Pharm. Sci., 98, pp. 4413-4419 Chavda, H.V., Patel, C.N., Anand, I.S., Biopharmaceutical classification system (2010) Syst. Rev. Pharm., 1, pp. 62-69 Huber, P.C., Maruiama, C.H., Almeida, W.P., Glicoproteína-P, resistência a múltiplas drogas (MDR) e relação estrutura-atividade de moduladores (2010) Quim. Nova, 33, pp. 2148-2154 Fruttero, R., Ferrarotti, B., Serafino, A., Stiloa, D., Gasco, A., Unsummetrically substituted furoxans, Part 11, methylfuroxancarbaldehydes (1989) J. Heterocycl. Chem., 26, pp. 1345-1347 Gasco, A.M., Fruttero, R., Sorba, G., Gasco, A., Unsymmetrically substituted furoxans, Part XIII, phenylfuroxancarbaldehydes and related compounds (1991) Liebigs Ann. Chem., pp. 1211-1213 Braman, R.S., Hendrix, S.A., Nanogram nitrite and nitrate determination in enviromental and biological materials by vanadium(III) reduction with chemiluminescence detection (1989) Anal. Chem., 61, pp. 2715-2718 Castegnaro, (1978) Food Addit. Contam., 4, pp. 37-43 Eakin, A.E., Mills, A.A., Harth, G., McKerrow, J.H., Craik, C.S., The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi (1992) J. Biol. Chem., 267, pp. 7411-7420 Li, R., Kenyon, G.L., Cohen, F.E., Chen, X., Gong, B., Dominguez, J.N., Davidson, E., McKerrow, J.H., In vitro antimalarial activity of chacones and their derivatives (1995) J. Med. Chem., 38, pp. 5031-5037 Borchardt, D.M., Mascarello, A., Chiaradia, L.D., Nunes, R.J., Oliva, G., Yunes, R.A., Andricopulo, A.D., Biochemical evaluation of a series of synthetic chalcone and hydrazide derivatives as novel inhibitors of cruzain from Trypanosoma cruzi (2010) J. Braz. Chem. Soc., 21, pp. 142-150 Gonçalves, J.E., Fernandes, M.B., Chiann, C., Gai, M.N., Souza, J., Storpirtis, S., Effect of pH, mucin and bovine serum on rifampicin permeability through Caco-2 cells (2012) Biopharm. Drug. Dispos., 33, pp. 316-323